PK MED Strengthens Its Strategic and Scientific Governance to Support the Development of Its Therapeutic Micro-implants

Contributed by: Business Wire

Tags

Biotechnology

FDA

Other Health

Health

Clinical Trials

PK MED

More Like This

PK MED Receives €1.5M DeepTech Non-Dilutive Financing From Bpifrance for the Development of a Local Cell-Homing Implant to Enhance Bone Marrow Transplantation

PK MED Announces FDA Clearance to Initiate Its Clinical Program for PKM-01, for Local Treatment of Gout Flares, Directly by a Phase 2 Trial

François Ravenelle, PhD, President and Chief Executive Officer of Innospera Pharma

François Ravenelle, PhD Appointed President and CEO of Innospera Pharma to Lead Next Phase of Growth

MRM Health Strengthens Board with Michel Detheux as Chairman and Hans-Jürgen Wörle as Independent Director as MH002 Advances Through Phase 2b

Brenus Pharma Strengthens Its Governance With Designation of a New President and Appointment of Former Novo Nordisk EVP as Independent Member

4P-Pharma welcomes Marina Vasiliou, Christian Bechon and Alain Sainsot as independent members of its board (Photo: Business Wire)

4P-Pharma Welcomes Marina Vasiliou, Christian Bechon, and Alain Sainsot as Independent Members of Its Board

EGLE Therapeutics Strengthens its Board of Directors with the Appointment of Michel Detheux, Ph.D., as Independent Chairman Board Member, and with the Appointment of Mojgan Hossein-Nia, Ph.D. as Board Member Representative of Takeda Ventures

From left to right: Chris Perkin, Executive Chairman of the Board (Altasciences), and Marie-Hélène Raigneau, Chief Executive Officer (Altasciences).

Altasciences Announces Chris Perkin Appointed Executive Chairman; Marie-Hélène Raigneau Appointed Chief Executive Officer